![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NT5C |
Gene summary for NT5C |
![]() |
Gene information | Species | Human | Gene symbol | NT5C | Gene ID | 30833 |
Gene name | 5', 3'-nucleotidase, cytosolic | |
Gene Alias | DNT | |
Cytomap | 17q25.1 | |
Gene Type | protein-coding | GO ID | GO:0000255 | UniProtAcc | Q8TCD5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
30833 | NT5C | LZE2D | Human | Esophagus | HGIN | 3.51e-04 | 4.29e-01 | 0.0642 |
30833 | NT5C | LZE2T | Human | Esophagus | ESCC | 1.15e-06 | 9.43e-01 | 0.082 |
30833 | NT5C | LZE4T | Human | Esophagus | ESCC | 1.78e-31 | 9.27e-01 | 0.0811 |
30833 | NT5C | LZE7T | Human | Esophagus | ESCC | 1.71e-05 | 5.30e-01 | 0.0667 |
30833 | NT5C | LZE8T | Human | Esophagus | ESCC | 2.34e-02 | -2.32e-02 | 0.067 |
30833 | NT5C | LZE20T | Human | Esophagus | ESCC | 1.12e-10 | 4.21e-01 | 0.0662 |
30833 | NT5C | LZE21D1 | Human | Esophagus | HGIN | 5.88e-07 | 8.64e-01 | 0.0632 |
30833 | NT5C | LZE22D1 | Human | Esophagus | HGIN | 2.96e-11 | 6.48e-01 | 0.0595 |
30833 | NT5C | LZE22T | Human | Esophagus | ESCC | 5.80e-10 | 9.59e-01 | 0.068 |
30833 | NT5C | LZE24T | Human | Esophagus | ESCC | 5.71e-41 | 1.26e+00 | 0.0596 |
30833 | NT5C | LZE22D3 | Human | Esophagus | HGIN | 2.10e-07 | 4.96e-01 | 0.0653 |
30833 | NT5C | LZE21T | Human | Esophagus | ESCC | 1.36e-13 | 1.11e+00 | 0.0655 |
30833 | NT5C | P1T-E | Human | Esophagus | ESCC | 1.36e-15 | 8.33e-01 | 0.0875 |
30833 | NT5C | P2T-E | Human | Esophagus | ESCC | 2.35e-55 | 9.43e-01 | 0.1177 |
30833 | NT5C | P4T-E | Human | Esophagus | ESCC | 1.01e-50 | 1.14e+00 | 0.1323 |
30833 | NT5C | P5T-E | Human | Esophagus | ESCC | 6.49e-34 | 6.79e-01 | 0.1327 |
30833 | NT5C | P8T-E | Human | Esophagus | ESCC | 2.36e-63 | 1.05e+00 | 0.0889 |
30833 | NT5C | P9T-E | Human | Esophagus | ESCC | 2.34e-55 | 1.26e+00 | 0.1131 |
30833 | NT5C | P10T-E | Human | Esophagus | ESCC | 1.34e-97 | 1.56e+00 | 0.116 |
30833 | NT5C | P11T-E | Human | Esophagus | ESCC | 7.35e-33 | 1.78e+00 | 0.1426 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
GO:000095618 | Esophagus | ESCC | nuclear-transcribed mRNA catabolic process | 88/8552 | 112/18723 | 9.41e-13 | 4.14e-11 | 88 |
GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:190331316 | Esophagus | ESCC | positive regulation of mRNA metabolic process | 87/8552 | 118/18723 | 5.10e-10 | 1.32e-08 | 87 |
GO:006101319 | Esophagus | ESCC | regulation of mRNA catabolic process | 115/8552 | 166/18723 | 5.90e-10 | 1.49e-08 | 115 |
GO:004348719 | Esophagus | ESCC | regulation of RNA stability | 117/8552 | 170/18723 | 7.91e-10 | 1.94e-08 | 117 |
GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
GO:004348819 | Esophagus | ESCC | regulation of mRNA stability | 109/8552 | 158/18723 | 2.40e-09 | 5.35e-08 | 109 |
GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
GO:006101416 | Esophagus | ESCC | positive regulation of mRNA catabolic process | 63/8552 | 87/18723 | 3.70e-07 | 5.15e-06 | 63 |
GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
GO:006115716 | Esophagus | ESCC | mRNA destabilization | 61/8552 | 84/18723 | 4.81e-07 | 6.49e-06 | 61 |
GO:005077916 | Esophagus | ESCC | RNA destabilization | 63/8552 | 88/18723 | 7.23e-07 | 9.40e-06 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa002405 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa0024012 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa00240 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa002401 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0024021 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
hsa0123231 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0024031 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NT5C | insertion | Frame_Shift_Ins | novel | c.565_566insCTCACGCCTATAATCCCAGCACTTTGGGA | p.Glu189AlafsTer13 | p.E189Afs*13 | Q8TCD5 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
NT5C | SNV | Missense_Mutation | rs146917283 | c.272C>T | p.Pro91Leu | p.P91L | Q8TCD5 | protein_coding | tolerated(0.06) | benign(0.085) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NT5C | SNV | Missense_Mutation | c.395N>T | p.Arg132Met | p.R132M | Q8TCD5 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
NT5C | SNV | Missense_Mutation | c.305T>C | p.Leu102Pro | p.L102P | Q8TCD5 | protein_coding | deleterious(0.01) | benign(0.051) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
NT5C | SNV | Missense_Mutation | novel | c.445N>T | p.Val149Phe | p.V149F | Q8TCD5 | protein_coding | deleterious(0.01) | benign(0.225) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NT5C | SNV | Missense_Mutation | c.226N>T | p.Pro76Ser | p.P76S | Q8TCD5 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NT5C | SNV | Missense_Mutation | novel | c.191N>C | p.Val64Ala | p.V64A | Q8TCD5 | protein_coding | deleterious(0.02) | benign(0.272) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NT5C | SNV | Missense_Mutation | rs576379965 | c.478C>T | p.His160Tyr | p.H160Y | Q8TCD5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NT5C | SNV | Missense_Mutation | novel | c.524N>T | p.Pro175Leu | p.P175L | Q8TCD5 | protein_coding | deleterious(0.01) | benign(0.059) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
NT5C | SNV | Missense_Mutation | novel | c.598N>T | p.Arg200Trp | p.R200W | Q8TCD5 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
30833 | NT5C | ENZYME | lamivudine | LAMIVUDINE | ||
30833 | NT5C | ENZYME | gemcitabine | GEMCITABINE | 25162786 |
Page: 1 |